NASDAQ:HCM
实时
15.50
-0.10
-0.64%
2025-04-23 09:47:42
-
今开：15.42
昨收：15.60
-
今日区间：15.39-15.42
52周区间：11.93-21.92
-
成交量：0.50涓�
成交额：7.65万
-
市 值：26.97亿
市盈率：70.78
-
贝塔系数：
每股收益：0.219
盘前
15.43
-0.17
-1.09%
成交量 0.05涓�
2025-04-23 09:30
董事会
- Dan Eldar
- Dan Eldar currently works at HUTCHMED (China) Ltd., as Chairman from 2024, Hutchison Water Israel E.P.C Ltd., as Director, S.D. Sight Diagnostics Ltd., as Director from 2019, Hutchison Biofilm Medical Solutions Ltd., as Director, DayTwo Ltd., as Director from 2019, and Longliv Ventures LP, as Managing Director from 2018. Dr. Eldar also formerly worked at Max It Finance Ltd., as Independent Non-Executive Director, Hutchison Kinrot, as Director, Leumi Card Ltd., as Independent Non-Executive Director, Leumi Card Ltd., as Member of the Board of Directors from 2013 to 2016, Partner Communications Co. Ltd., as Vice President-Investor Relations, and AceAge, Inc., as Board Member from 2020 to 2022. Dr. Eldar received his graduate degree and doctorate degree from Harvard University and undergraduate degree and graduate degree from The Hebrew University of Jerusalem.
-
- Edith Shih
- Edith Shih currently works at Accounting & Financial Reporting Council, as Chairman-Process Review Panel, Maritime Transport Services Ltd., as Director, Port of Felixstowe Ltd., as Director from 1997, and various other companies. Ms. Shih also formerly worked at China Oceanwide Holdings Ltd., as Secretary & Executive Director from 2012 to 2014, VC Capital Ltd., as Director from 1989 to 1991, H3G SpA, as Director, and various other companies. Ms. Shih received her graduate degree from The Trustees of Columbia University in The City of New York and undergraduate degree and graduate degree from the University of the Philippines.
-
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
- Chig Fung Cheng
- Chig Fung Cheng currently works at HUTCHMED (China) Ltd., as Chief Financial Officer & Executive Director from 2011, Hutchison MediPharma Ltd., as Director, Sen Medicine Co. Ltd., as Director, Hutchison Medipharma (Hong Kong) Ltd., as Director, Hutchison Medipharma (Suzhou) Ltd., as Director, The Institute of Chartered Accountants in Australia, as Member, and Chartered Accountants Australia & New Zealand, as Member. Mr. Cheng also formerly worked at Hutchison Healthcare Ltd., as Director, Bristol-Myers Squibb (China) Investment Co. Ltd., as Director from 2006 to 2008, Sino-American Shanghai Squibb Pharmaceuticals Ltd., as Director, PricewaterhouseCoopers (Australia), as Auditor, Bristol-Myers Squibb (China) Pharmaceuticals Co. Ltd., as Vice President-Finance, Nestl (China) Ltd., as Controller, and KPMG Beijing, as Auditor. Mr. Cheng received his undergraduate degree from the University of Adelaide.
-
旧服务已下线，请迁移至 http://api.fanyi.baidu.com
- Wei Guo Su
- Wei Guo Su currently works at HUTCHMED (China) Ltd., as CEO, Executive Director & Chief Scientific Officer from 2022 and Hutchison MediPharma Ltd., as Chief Scientific Officer & Executive VP from 2012. Dr. Su also formerly worked at Pfizer Inc., as Director-Medicinal Chemistry Department. Dr. Su received his doctorate degree from Harvard University and undergraduate degree from Fudan University.
-
- Dan Eldar
- Dan Eldar currently works at HUTCHMED (China) Ltd., as Chairman from 2024, Hutchison Water Israel E.P.C Ltd., as Director, S.D. Sight Diagnostics Ltd., as Director from 2019, Hutchison Biofilm Medical Solutions Ltd., as Director, DayTwo Ltd., as Director from 2019, and Longliv Ventures LP, as Managing Director from 2018. Dr. Eldar also formerly worked at Max It Finance Ltd., as Independent Non-Executive Director, Hutchison Kinrot, as Director, Leumi Card Ltd., as Independent Non-Executive Director, Leumi Card Ltd., as Member of the Board of Directors from 2013 to 2016, Partner Communications Co. Ltd., as Vice President-Investor Relations, and AceAge, Inc., as Board Member from 2020 to 2022. Dr. Eldar received his graduate degree and doctorate degree from Harvard University and undergraduate degree and graduate degree from The Hebrew University of Jerusalem.
-
- Paul Rutherford Carter
- Paul Rutherford Carter is currently the Non-Executive Chairman at Evox Therapeutics Ltd., the Senior Independent Non-Executive Director at HUTCHMED (China) Ltd., the Director at Concentric Analgesics, Inc., the Independent Non-Executive Director at Immatics NV, the Director at VectivBio AG, the Independent Non-Executive Director at Awakn Life Sciences Corp., the Director at Echosens SA, and the Independent Director at OPEN Health Communications LLP. He previously worked as an Independent Director at Mallinckrodt Plc, Lundbeck Seattle BioPharmaceuticals, Inc., VectivBio Holding AG, Gilead Sciences, Inc., and GSK Plc. He obtained his undergraduate degree from the University of West London in 1983.
-
- Graeme Allan Jack
- Mr. Graeme A. Jack is an Independent Non-Executive Director at CK Hutchison Holdings Ltd., an Independent Non-Executive Director at HUTCHMED (China) Ltd., an Independent Non-Executive Director at Greenbrier Cos., Inc., an Associate at Chartered Accountants Australia & New Zealand and an Independent Trustee at Hutchison Provident & Retirement Plan. He is on the Board of Directors at CK Hutchison Holdings Ltd., HUTCHMED (China) Ltd., Greenbrier Cos., Inc. and Hutchison Provident & Retirement Plan. Mr. Jack was previously employed as an Independent Non-Executive Director by COSCO SHIPPING Development Co., Ltd., an Independent Non-Executive Director by Graff Diamonds Corp., an Independent Non-Executive Director by Hutchison Port Holdings Management Pte Ltd. (Singapore), an Independent Non-Executive Director by Hutchison Port Holdings Trust, and a Partner by PricewaterhouseCoopers LLP. He received his undergraduate degree from The University of New South Wales.
-
- Shu Kam Mok
- Dr. Shu Kam Mok, MD, is an Independent Non-Executive Director at AstraZeneca PLC, an Independent Non-Executive Director at HUTCHMED (China) Ltd., a Chairman at Sanomics Ltd., a Non-Executive Independent Director at Lunit Usa, Inc. and a Secretary at Chinese Society of Clinical Oncology. He is on the Board of Directors at AstraZeneca PLC, HUTCHMED (China) Ltd., American Society of Clinical Oncology, Inc. and Lunit Usa, Inc. Dr. Mok was previously employed as a Chairman by Act Genomics Co. Ltd., a Co-Founder by Asia Thoracic Oncology Research Group, a Co-Founder by Aurora Tele-Oncology Ltd., a Co-Founder by Chinese Thoracic Oncology Group, a Treasurer by International Association for the Study of Lung Cancer, and a Chairman-Clinical Oncology Department by The Chinese University of Hong Kong. He received his undergraduate degree from the University of Alberta and a doctorate degree from the University of Alberta.
-
- Ling Yang
- Ling Yang currently works at Hangzhou Adicon Clinical Laboratories, Inc., as Chairman from 2018, ADICON Holdings Ltd., as Non-Executive Chairman from 2018, HUTCHMED (China) Ltd., as Non-Executive Director from 2023, Ambio Pharmaceuticals, as Non-Executive Director from 2021, Ambio, Inc., as Director, Carlyle Asia Investment Advisors Ltd., as Managing Director from 2011, and The Phi Beta Kappa Society, as Member. Ms. Yang also formerly worked at Shenzhen Salubris Pharmaceuticals Co., Ltd., as Director, Ambio Holdings, Inc., as Director, The Carlyle Group Inc., as Vice President & Managing Director, KKR Asia Ltd., as Principal from 2008 to 2011, The Carlyle Group Inc., as Associate from 2005 to 2006, and Kohlberg Kravis Roberts & Co.(Beijing), as Principal from 2008 to 2011. Ms. Yang received her undergraduate degree in 2002 from Smith College and Masters Business Admin degree in 2008 from Harvard Business School.
-
- Renu Bhatia
- Renu Bhatia currently works at HUTCHMED (China) Ltd., as Independent Non-Executive Director from 2024 and Opharmic Technology (HK) Ltd., as Director. Dr. Bhatia received her graduate degree from The University of Hong Kong, doctorate degree from the University of London, and Masters Business Admin degree from Yale University.
-
- Chao Hong Hu
- Chao Hong Hu was the founder of Shanghai Miracogen, Inc. since 2014, holding the title of Chairman & General Manager. Current job includes Independent Non-Executive Director at HUTCHMED (China) Ltd. since 2024. Former jobs include Co-Chief Executive Officer & Executive Director at Lepu Biopharma Co., Ltd. from 2020 to 2024, Director-Molecular Biology & Clinical Immunology at ID Biomedical Corp., Director-Bioassay Development & Process Analytics at Seagen, Inc. from 2007 to 2013, and Head-Molecular Biology & Clinical Immunology at GSK Plc from 2006 to 2007. Education includes an undergraduate degree from Wuhan University conferred in 1986 and a doctorate from the Chinese Academy of Sciences.
-